In a regulatory filing, Neurocrine Biosciences chief HR officer Julie Cooke disclosed the sale of 11,397 common shares of the company on May 1 at a price of $103.8913 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine Biosciences Reports First Quarter 2023 Financial Results
- Neurocrine reports Q1 adjusted EPS (51c), consensus 13c
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Neurocrine price target raised to $110 from $108 at RBC Capital
- Neurocrine price target lowered to $127 from $131 at Citi